ATP7A is a novel target of retinoic acid receptor beta2 in neuroblastoma cells

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Biology

Background:

• Retinoic acid receptor beta 2 (RARbeta(2)) expression is crucial for retinoid anticancer effects.
• Low RARbeta(2) expression is observed in advanced neuroblastoma, suggesting a tumor suppressor role.
• The copper efflux pump, ATP7A, is a retinoid-responsive gene.

Purpose of the Study:

• To investigate the role of RARbeta(2) in neuroblastoma growth inhibition.
• To elucidate the relationship between RARbeta(2), ATP7A, and copper metabolism in retinoid-treated neuroblastoma cells.

Main Methods:

• Overexpression of RARbeta(2) and its ABC domain in neuroblastoma cells.
• RNA interference (siRNA) to downregulate RARbeta(2) and ATP7A.
• Assessment of ATP7A expression, copper efflux, cell viability, and proliferation.

Main Results:

• The RARbeta(2) ABC domain alone mediated growth inhibition in neuroblastoma cells.
• Ectopic RARbeta(2) overexpression upregulated ATP7A, and its ABC domain induced ATP7A expression.
• RARbeta(2) siRNA blocked ATP7A induction by retinoids.
• ATP7A downregulation reduced copper efflux and increased cell viability.
• Copper supplementation enhanced cell growth and reduced retinoid responsiveness, while chelation decreased viability.

Conclusions:

• ATP7A expression is regulated by retinoic acid receptor beta.
• RARbeta(2)-mediated regulation of ATP7A influences intracellular copper levels.
• This study reveals a novel link between retinoid anticancer mechanisms and copper metabolism in neuroblastoma.